Microdosing: The Complete Guide to Psilocybin Truffles & Mushrooms

Microdosing is the practice of taking sub-perceptual doses of psychedelic substances — typically 1/10th to 1/20th of a recreational dose. The goal is not to "trip" but to experience subtle improvements in mood, creativity, focus, and emotional well-being over weeks or months of regular use.

The practice gained mainstream attention through Dr. James Fadiman's research in the 2010s, though indigenous cultures have used small doses of psilocybin mushrooms and other psychedelics for centuries. Today, microdosing psilocybin truffles is legal in the Netherlands, making Dutch smartshops the primary source for Europeans looking to explore this practice.

This guide covers everything you need to know: proven protocols, exact dosages, where to buy, real experiences, scientific evidence, and important safety information.

Mycologist Paul Stamets — one of the world's foremost experts on fungi — developed a microdosing stack that goes beyond psilocybin alone. The Stamets Stack combines three ingredients taken together on dosing days: a psilocybin microdose (0.1–0.3 g dried truffle equivalent), lion's mane mushroom (Hericium erinaceus, 50–200 mg extract), and niacin (vitamin B3, 100–200 mg flush form).

The schedule is 4 days on, 3 days off. Stamets hypothesises that lion's mane stimulates nerve growth factor (NGF) production while psilocybin promotes neuroplasticity — together targeting neurogenesis more powerfully than either alone. The niacin flush is thought to help transport the compounds into the peripheral nervous system. This stack is not for beginners: start with a standard Fadiman Protocol for at least one full cycle before considering it.

Read the full protocol comparison →

The scientific landscape around psilocybin has shifted dramatically over the past decade. Roland Griffiths at Johns Hopkins University — who published landmark studies on psilocybin-assisted therapy for depression and addiction — helped establish the field as mainstream science. Robin Carhart-Harris, formerly at Imperial College London and now at UCSF, has produced some of the most cited neuroimaging research showing how psilocybin resets the default mode network.

In the Netherlands, researchers at Leiden University and Maastricht University have contributed key studies on the cognitive effects of psilocybin truffles — including work on creativity, emotional processing, and microdosing outcomes in naturalistic settings. The FDA granted Breakthrough Therapy designation to psilocybin for treatment-resistant depression in 2018, accelerating clinical development worldwide.

It is important to distinguish full-dose clinical psilocybin therapy from microdosing. Clinical therapy involves a single high dose (25–35 mg psilocybin) administered in a controlled setting with trained guides, targeting transformative experiences that reset entrenched thought patterns. Microdosing uses sub-perceptual amounts taken regularly over weeks. Both approaches appear to leverage the same underlying neuroplasticity mechanism — psilocybin's agonism of 5-HT2A receptors promotes synaptic growth and loosens rigid cognitive patterns — but through very different intensity and duration profiles.